Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SGK1 | O00141 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17738626 | 0.85 | DYRK1A (0.46) | METTL3 | |
| SCHEMBL17738624 | 0.81 | HSP90AA1 (0.57) | METTL3METAP2 | |
| SCHEMBL17738640 | 0.81 | METAP2 (0.43) | METAP2ALOX15SGK1 | |
| SCHEMBL17738290 | 0.79 | METTL3 (0.66) | METTL3IDO1 | |
| SCHEMBL2592578 | 0.78 | NR4A2 (0.48) | LMNAMETAP2IDO1 | |
| SCHEMBL17738415 | 0.76 | METTL3 (0.53) | METTL3IDO1 | |
| SCHEMBL18710630 | 0.76 | METAP2 (0.49) | METAP2IDO1 | |
| SCHEMBL24029085 | 0.72 | MAOB (0.42) | METTL3ALOX15SGK1 | |
| SCHEMBL13373591 | 0.69 | DRD2 (0.44) | LMNA | |
| SCHEMBL20939016 | 0.69 | IDO1 (0.36) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130738-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (GB) | 2021-09-28 | — | — | US | disclosed |
| US-20200172492-A1 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD. (GB) | 2020-06-04 | — | — | US | disclosed |
| US-10590086-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (GB) | 2020-03-17 | — | — | US | disclosed |
| WO-2016071293-A2 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD (GB) | 2016-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130738-B2 | Pharmaceutical compound | IDO1, TDO2, IDO2 | METTL3 1227/4885LMNA 4120/4885METAP2 840/4885 |
| US-20200172492-A1 | PHARMACEUTICAL COMPOUND | IDO1, TDO2, IDO2 | METTL3 1227/4885LMNA 4120/4885METAP2 840/4885 |
| US-10590086-B2 | Pharmaceutical compound | IDO1, TDO2, IDO2 | METTL3 1227/4885LMNA 4120/4885METAP2 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.